Nuveen Asset Management LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,793,571 shares of the company’s stock after selling 462,644 shares during the period. Johnson & Johnson comprises 1.0% of Nuveen Asset Management LLC’s portfolio, making the stock its 10th largest holding. Nuveen Asset Management LLC’s holdings in Johnson & Johnson were worth $2,071,011,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Tamarack Advisers LP acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $18,035,000. Orser Capital Management LLC boosted its holdings in Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock worth $272,000 after buying an additional 575 shares during the last quarter. S.E.E.D. Planning Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth $387,000. Morse Asset Management Inc grew its stake in Johnson & Johnson by 4.8% in the fourth quarter. Morse Asset Management Inc now owns 33,470 shares of the company’s stock valued at $4,882,000 after acquiring an additional 1,525 shares during the period. Finally, Spreng Capital Management Inc. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $2,757,000. 68.51% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE JNJ opened at $147.80 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The company has a 50 day simple moving average of $148.86 and a two-hundred day simple moving average of $143.59. The stock has a market cap of $388.08 billion, a price-to-earnings ratio of 19.31, a PEG ratio of 3.20 and a beta of 0.70.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.10 EPS. Analysts forecast that Johnson & Johnson will post 7.68 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.01 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date was Friday, May 22nd. This represents a $4.04 annualized dividend and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Several research analysts recently commented on JNJ shares. Morgan Stanley increased their target price on shares of Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Credit Suisse Group restated a “buy” rating and set a $161.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Barclays lifted their price objective on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a report on Tuesday, April 28th. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $163.47.
In related news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average price of $127.69 per share, with a total value of $63,845.00. Following the completion of the acquisition, the director now owns 16,030 shares in the company, valued at $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: High-Yield Dividend Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.